5 sources checked · 2 source groups included · 1h ago
Still Watching
FDA panel backs first-of-its-kind flu vaccine using m RNA technology
A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
1 Left4 Center0 Right
Still watching.Optics is waiting for a cleaner match before calling the split.
STILL WATCHING
As of June 18, 2026 at 10:31 PM, this is how Optics News reads the wording differences in this story.
What happenedA new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same m RNA technology that was key to ending the COVID-19 pandemic.
The headline splitThe left frames it as "FDA panel backs first-of-its-kind flu vaccine using m RNA technology". The center frames it as "STAT+: FDA advisory panel endorses Moderna m RNA flu vaccine that was subject of controve...".
Match confidenceMedium confidence. 5 sources across 2 bias buckets. Useful framing signal — check the source list before sharing.
Same-event confidenceMedium
5 sources across 2 bias buckets agree on the event.
Framing confidenceModerate
54/99 — meaningful wording shift across the spectrum.
WHAT EACH SIDE EMPHASIZED
Left / center-leftFDA panel backs first-of-its-kind flu vaccine using m RNA technology
PBS NewsHour · Center-left · News report
CenterFDA panel backs first-of-its-kind flu vaccine using m RNA technology
WJW FOX8 (Nexstar, Cleveland) · Center · News report
Right / center-rightNo matching source in this bucket yet.
FDA panel backs first-of-its-kind flu vaccine using m RNA technology
A new kind of flu vaccine moved a step closer to the U.S. market Thursday as federal health advisers recommended approval of the first made with the same m RNA technology that was key to en...
FDA panel recommends m RNA flu vaccine for older adults
A first-of-its-kind flu shot is a step closer to being available to the public after a Food and Drug Administration (FDA) advisory panel voted Thursday to recommend Moderna’s m RNA-based va...
STAT+: FDA advisory panel endorses Moderna m RNA flu vaccine that was subject of controversy
A panel of advisers to FDA gave its endorsement to a seasonal m RNA flu vaccine that was developed by Moderna and that earlier this year became the subject of controversy.
